An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Thompson Street Capital Partners has acquired Vector Laboratories, part of Maravai, enhancing its presence in the life sciences sector. Vector specializes in labeling and visual detection reagents for academic and corporate research. The acquisition aims to leverage TSCP's expertise to foster growth and capitalizes on market opportunities. CEO Lisa V. Sellers highlighted TSCP's role in enhancing Vector’s operations. The deal is expected to propel Vector's strategic and organic growth in a competitive environment.
Positive
Acquisition enhances TSCP's capabilities in the life sciences sector.
Vector Laboratories has a solid reputation and established market presence.
Potential for both organic and strategic growth post-acquisition.
Negative
None.
ST. LOUIS--(BUSINESS WIRE)--
Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced it has acquired Vector Laboratories, the Protein Detection business unit of Maravai (NASDAQ: MRVI). Vector Laboratories is a manufacturer of labeling and visual detection reagents for life science researchers doing tissue-based protein detection and characterization. The acquisition of Vector adds to TSCP’s experience in life sciences.
“Maravai has been critical in helping strengthen Vector Laboratories’ operations, including innovative solutions to better serve our academic and early development stage customers,” said Lisa V. Sellers, Ph.D., Vector’s Chief Executive Officer. “We’re excited to partner with Thompson Street Capital Partners, as their knowledge of the research reagents space provides an immediate opportunity to position the Company for both organic and strategic growth and take advantage of what we believe are tremendous opportunities in the marketplace.”
Vector Laboratories provides consumable reagents used in slide staining and imaging workflows within life science research, allowing scientists to better locate and identify certain proteins within a tissue sample. Vector’s primary end markets are academic research labs and corporations, provided either directly to customers or via distributors and resellers.
“Vector Laboratories has been an established, well-respected and innovative manufacturer in the life science sector for decades, and we’re excited to be partnering with Dr. Sellers and the Vector team to achieve the next phase of the Company’s growth,” said Bob Dunn, Managing Partner at TSCP. Added J.C. Wetzel, Director at TSCP, “Our experience in the life sciences sector allows us to understand the importance of what Vector provides to its customers as well as recognize the long-term potential for continued evolution.”
About Thompson Street Capital Partners
Thompson Street Capital Partners (www.tscp.com) is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses in the Life Sciences & Healthcare, Software & Technology, and Business and Consumer Services and Products sectors. Founded in 2000, the firm has acquired more than 150 companies and has managed more than $2.6 billion in equity. TSCP partners with management teams to increase value by accelerating growth, both organically and via acquisitions.
